Patient
|
Age
|
Stage
|
Histology
|
GRADE
|
ER%
|
PR%
|
HER2
|
MIB-1%
|
---|
L101
|
33
|
T2N2M0
|
invasive ductal
|
3
|
70
|
30
|
NEG
|
30
|
L103
|
48
|
T1N0M0
|
invasive ductal
|
2
|
85
|
100
|
3+
|
10
|
L106
|
36
|
T1N0M0
|
invasive ductal
|
3
|
70
|
90
|
NEG
|
20
|
L116
|
54
|
T1N1M0
|
invasive ductal
|
3
|
90
|
90
|
3+
|
10
|
L118
|
75
|
T4N1M0
|
invasive ductal
|
3
|
NEG
|
NEG
|
3+
|
20
|
L122
|
75
|
T2N0M0
|
invasive ductal
|
3
|
NEG
|
NEG
|
NEG
|
80
|
L128
|
44
|
T1N0M0
|
invasive ductal
|
3
|
90
|
20
|
NEG
|
20
|
L133
|
81
|
T4N0M0
|
invasive ductal
|
2
|
80
|
60
|
2+
|
5–10
|
L154
|
70
|
T1N0M0
|
invasive ductal
|
3
|
80
|
70
|
NEG
|
30
|
L176
|
74
|
T2N1M0
|
invasive ductal
|
3
|
NEG
|
NEG
|
2+
|
35
|
L180
|
77
|
T4N1M0
|
invasive ductal
|
2
|
100
|
70–80
|
3+
|
10–20
|
L181
|
63
|
T1N0M0
|
invasive ductal
|
1
|
75
|
NEG
|
NEG
|
35
|
L190
|
49
|
T3N1M0
|
invasive ductal
|
2
|
65
|
5
|
2+
|
20
|
L42
|
51
|
T4N1M0
|
invasive ductal
|
3
|
70
|
70
|
NEG
|
<5
|
L53
|
69
|
T4N0M0
|
invasive ductal
|
3
|
NEG
|
NEG
|
NEG
|
30
|
L67
|
61
|
T4N0M0
|
invasive ductal
|
3
|
NEG
|
NEG
|
NEG
|
30
|
L143
|
68
|
T1N0M0
|
invasive lobular
| |
20
|
30
|
1+
|
<5
|
L187
|
57
|
T2N1M0
|
invasive lobular
| |
90
|
NEG
|
NEG
|
10
|
L40
|
52
|
T4N2M0
|
invasive lobular
| |
NEG
|
NEG
|
2+
|
10
|
L43
|
51
|
T2N1M0
|
invasive lobular
| |
30
|
70
|
NEG
|
<5
|
L174
|
29
|
T1N0M0
|
medullary
|
3
|
NEG
|
<5
|
NEG
|
70
|
L179
|
73
|
T1N0M0
|
mucinous
|
2
|
100
|
90
|
2+
|
5
|
L50
|
52
|
T2N1M0
|
tubulolobular
| |
30
|
NEG
|
NEG
|
30
|
- The age of patients, stage in the TNM classification, histology, grade of tumors and HER 2/neu (HER2), estrogen receptor (ER), progesterone receptor (PR), and nuclear protein Ki67 (MIB-1) percentage of immunostained cells are listed for each patient. The patients constituting the metastase positive group are in bold.